Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to slow kidney failure in High-Risk patients

NCT ID NCT07624305

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a combination of two drugs (balcinrenone and dapagliflozin) works better than dapagliflozin alone for people with advanced chronic kidney disease (stages 3b and 4). About 2,800 participants will take the combination or a placebo daily, alongside standard care. The goal is to see if the combo can delay kidney failure, reduce heart-related deaths, and prevent hospitalizations for heart failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Balcinrenone and dapagliflozin combination pill
What this could lead to
If successful, this combination could offer a new treatment option to slow kidney disease progression and reduce heart complications in patients with advanced chronic kidney disease.
What could go wrong
This is a large phase 3 trial, but it hasn't started yet. The benefits over existing treatment may be modest, and there are risks like high potassium levels or side effects from the new drug combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL INSUFFICIENCY CHRONIC

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Research Site

    Ciudad de Buenos Aires, C1425AGC, Argentina

  • Research Site

    Edmonton, Alberta, T6G 2P4, Canada

  • Research Site

    Winnipeg, Manitoba, R2V 3M3, Canada

  • Research Site

    London, Ontario, N6A 5A5, Canada

  • Research Site

    Toronto, Ontario, M4G 3E8, Canada

  • Research Site

    Waterloo, Ontario, N2T 0C1, Canada

  • Research Site

    Halifax, NS B3H 2Y9, Canada

  • Research Site

    Magdeburg, 39120, Germany

  • Research Site

    Kita-ku, 144-0001, Japan

  • Research Site

    Osaka, 553-0003, Japan

  • Research Site

    Olsztyn, 10-561, Poland

  • Research Site

    Warsaw, 02-507, Poland

  • Research Site

    Warsaw, 04-141, Poland

  • Research Site

    Węgrów, 07-100, Poland

  • Research Site

    Wroclaw, 50-981, Poland

  • Research Site

    Żywiec, 34-300, Poland

  • Research Site

    Anyang, 14068, South Korea

  • Research Site

    Cheonan-si, 31151, South Korea

  • Research Site

    Seoul, 03181, South Korea

  • Research Site

    Seoul, 03312, South Korea

  • Research Site

    Seoul, 04401, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 08308, South Korea

  • Research Site

    Changhua, 500, Taiwan

  • Research Site

    Hualien City, 970473, Taiwan

  • Research Site

    Kaohsiung City, 813, Taiwan

  • Research Site

    Kaohsiung City, 833, Taiwan

  • Research Site

    New Taipei City, 220216, Taiwan

  • Research Site

    Taichung, 40201, Taiwan

  • Research Site

    Taichung, 404, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Taichung, 433004, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Tainan, 710, Taiwan

  • Research Site

    Taipei, 100, Taiwan

  • Research Site

    Taipei, 110, Taiwan

  • Research Site

    Taipei, 116, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Zhubei, 302, Taiwan

  • Research Site

    Da Nang, 55000, Vietnam

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Hanoi, 10000, Vietnam

  • Research Site

    Hà Nội, 100000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

  • Research Site

    Hochiminh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.